Menu
Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.

NEW PARTNERSHIP ADVANCES CIRCULATING TUMOR CELL DETECTION RARECYTE AND LEICA BIOSYSTEMS CO-MARKET SLIDE-BASED ASSAY FOR FULLY AUTOMATED IMMUNO-STAINING OF CIRCULATING TUMOR CELLS

Published: 

MELBOURNE, AUSTRALIA & SEATTLE, WASHINGTON, October 15, 2015 – Leica Biosystems and RareCyte, Inc. (RareCyte) have announced the co-marketing of RareCyte's AccuCyte®-CyteFinder® rare cell analysis product line with Leica Biosystems' BOND RX research staining platform*.

With this partnership researchers now have access to a fully automated solution for immuno-staining of captured circulating tumor cells (CTCs) deposited on microscope slides, providing a key step to accelerating the development of clinical application for CTCs.

The RareCyte technology represents a major advancement in visual CTC detection, analysis, and single cell retrieval. By linking AccuCyte-CyteFinder with Leica Biosystems’ BOND RX platform, researchers will be able to easily collect CTCs and perform either immuno-histochemical (IHC) or immunofluorescence (IF) automated staining on a glass slide. With the CyteFinder automated image analysis system, cells may be analyzed in up to six IF channels for multiplexed phenotyping. This is followed by integrated single cell retrieval of identified CTCs for downstream analysis using technologies such as Next Generation Sequencing (NGS).

RareCyte’s AccuCyte-CyteFinder is being used by leading institutions for research and investigational diagnostic development. The BOND RX platform is an open and flexible system that efficiently automates staining. It provides a high-throughput workflow with exceptional consistency and minimal hands-on time.

"We are extremely pleased to partner with Leica Biosystems." said RareCyte CEO Ron Seubert. "This will enable us to provide an integrated platform that combines rare cell identification and single cell analysis capability.  This agreement will help make CTC analysis available broadly to the scientific and diagnostic research community.  It will further accelerate the investigation of potential blood-based cancer diagnostics."

 

Mr. Ralf Eckert, VP Innovations at Leica Biosystems added: “We are happy that our platform is facilitating the immuno-staining of captured circulating tumor cells. We will continually evolve the BOND RX platform in order to provide researchers with enhanced tools and help speed-up important discoveries in cancer diagnostics."

*For Research Use Only. Not for use in diagnostic procedures.

About Leica Biosystems

Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica’s easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 7 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at www.LeicaBiosystems.com.

About RareCyte, Inc

RareCyte is a Seattle-based life science research company focused on characterizing and isolating rare cells in blood. RareCyte is dedicated to bringing its innovative products to Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer, infectious disease and prenatal diagnostics. For more information about RareCyte, visit www.rarecyte.com.

Media Contact – RareCyte
Evan Castiglia, Vice-President of Business Development and Finance
ecastiglia@rarecyte.com
, +1 206-455-9097